Trial finds vitamin D supplements don't reduce COVID severity but could reduce long COVID risk
medicalxpress - In a large, randomized trial, researchers at Mass General Brigham found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes. Results of the study are published in The Journal of Nutrition.
AI Summary: A large randomized trial found high‑dose vitamin D3 did not lower acute COVID‑19 severity but revealed a surprising signal: supplementation may reduce the risk of developing long‑COVID. The result complicates the vitamin D narrative — not a cure, perhaps a modest shield against persistent post‑infectious symptoms worthy of further investigation.
Related Stories
Daily oral care more than halves hospital‑acquired pneumonia risk / 2 months
Gut microbe tied to Mediterranean diet boosts muscle strength in mice / 3 months
‘Oslo patient’ reaches HIV remission after rare stem‑cell transplant / 2 months
Study names five-a-day foods that best support heart health / 4 wks
Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 1 month
US gray‑market peptides face scrutiny as FDA panel debate looms / 7 days
The peptide problem: Hype outruns evidence, researchers caution / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pharmaceuticals, Hearing Loss, Diabetes, Healthcare and look for the RSS link.
StackHealth Time Machine